LehmanMillet adds two new accounts: Myriad Genetics and Breathe Technologies

HealthSTAR's LehmanMillet, the leading agency devoted to working with health care companies changing standards of care, today announced the addition of two new accounts: Myriad Genetics and Breathe Technologies.

"We are excited to partner with these courageous innovators," said Bruce Lehman, President and CEO, LehmanMillet. "The work they are doing represents important advances in diagnosis and treatment of conditions and diseases in which there are significant unmet medical needs. Bringing these standard-changers to patients and their doctors demands standard-changing education and communications."

Myriad Genetics, an early pioneer and current global leader in molecular diagnostics and genetic testing, has retained LehmanMillet to help raise awareness of BRACAnalysis®, the emerging standard of care for detecting hereditary breast and ovarian cancer risk. LehmanMillet recently launched JUST ASK™!, a public awareness campaign aimed at educating women and their doctors about the importance of knowing who is at risk and who should have BRACAnalysis®, a blood test that identifies the BRCA mutations responsible for most cases of hereditary breast and ovarian cancer. With a targeted combination of television, print, internet and social media, JUST ASK! encourages women to talk to their doctor if they have a family history of breast and/or ovarian cancer and to be aware of steps that can reduce their risk.

Breathe Technologies Inc. is developing a unique family of compact, ultra-lightweight, ambulatory respirator ventilator systems. Its device uses proprietary technology to leave a much smaller, lighter footprint than current ventilators, and it also requires less gas than larger units. The company believes its innovative technology will fill an unmet need for patients with severe ventilator insufficiency, both in the hospital setting and in the home.